Fact CheckerSign in

NCT07115940Recruiting

Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well - SELECT LATE Trial

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
408 (estimated)
First submitted
4 Aug 2025
Start date
13 Apr 2026
Primary completion date
1 Nov 2029
Lead sponsor
Amrou Sarraj
Diseases
Stroke
NCT number
NCT07115940

What you commit to

  • Study type: Interventional
  • Planned participants: 408
  • From 13 Apr 2026 to the primary completion date, 1 Nov 2029
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • General Inclusion Criteria:
  • Adults (18-85\* years) with the final diagnosis of an acute ischemic stroke$
  • NIHSS ≥ 6
  • Time from last-known-well to randomization \>24 - 72 hours
  • Pre-stroke modified Rankin Scale score of 0-1
  • Eligible for thrombectomy and medical management
  • Signed Informed Consent obtained
  • Subject willing to comply with the protocol follow-up requirements
  • Anticipated life expectancy of at least 3 months \*Inclusive of both 18 and 85 years of age (i.e. up to 86th birthdate). $Subacute presentation - In-hospital stroke admissions with fluctuating clinical symptoms for patients who presented to EVT centers within 24 hours of when they were last known well will not be eligible for the trial.
    • General Exclusion Criteria
  • Current participation in another investigational interventional drug or device study.
  • Baseline Platelet count \<100,000/μl
    • Imaging Inclusion Criteria
  • Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions), as determined by MR Angiography (MRA) or CT Angiography (CTA)
  • CT ASPECTS 3-10
  • CT Perfusion ischemic core (rCBF \<30%)# volume ≤150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume ≤150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.
    • Imaging Exclusion Criteria
  • Evidence of intracranial tumor (except small meningioma \<3cm without signs of edema or inflammation), acute intracranial hemorrhage, or arteriovenous malformation
  • Significant mass effect, defined as midline shift (\>3mm) using foramen of monroe (anterior margin of third ventricle) as the marker for midline instead of septum pellucidum AND/OR Effacement of sulci in contralateral hemisphere
  • Evidence of internal carotid artery dissection that is flow limiting or aortic dissection
  • Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device
  • Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
  • Any signs of established infarct, demarcating hypodensity and area of cerebral edema on non-contrast CT
  • CT ASPECTS 0-2
  • CT Perfusion ischemic core (rCBF \<30%)# volume \>150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume \>150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Chicago
Coordinator of this site? Confirm its status		ChicagoUnited StatesRecruiting
Baylor University Medical Center
Coordinator of this site? Confirm its status		DallasUnited StatesRecruiting
The University of Kansas Health System
Coordinator of this site? Confirm its status		Kansas CityUnited StatesRecruiting
West Virginia University
Coordinator of this site? Confirm its status		MorgantownUnited StatesRecruiting
Rhode Island Hospital
Coordinator of this site? Confirm its status		ProvidenceUnited StatesRecruiting
Washington University School of Medicine
Coordinator of this site? Confirm its status		St LouisUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.